Keyword: Heron Therapeutics
Heron posted new positive phase 2 results for its long-acting anesthetic, HTX-011, in total knee replacements and breast augmentation surgeries.
Heron Therapeutics' long-acting local anesthetic reduced pain intensity and opioid use following surgery.
Heron Therapeutics has gained an FDA approval for its long-acting, anti-nausea drug Sustol. This comes after about 6 years of regulatory back-and-forth.